- Home
- JPI vs HRTX Comparison
JPI vs HRTX Comparison
Compare JPI & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JPI
- HRTX
- Stock Information
- Founded
- JPI 2012
- HRTX 1983
- Country
- JPI United States
- HRTX United States
- Employees
- JPI N/A
- HRTX N/A
- Industry
- JPI Finance Companies
- HRTX Biotechnology: Pharmaceutical Preparations
- Sector
- JPI Finance
- HRTX Health Care
- Exchange
- JPI Nasdaq
- HRTX Nasdaq
- Market Cap
- JPI 288.1M
- HRTX 325.0M
- IPO Year
- JPI N/A
- HRTX 1987
- Fundamental
- Price
- JPI $20.43
- HRTX $1.75
- Analyst Decision
- JPI
- HRTX Strong Buy
- Analyst Count
- JPI 0
- HRTX 2
- Target Price
- JPI N/A
- HRTX $5.00
- AVG Volume (30 Days)
- JPI 54.7K
- HRTX 914.3K
- Earning Date
- JPI 01-01-0001
- HRTX 08-11-2025
- Dividend Yield
- JPI 6.15%
- HRTX N/A
- EPS Growth
- JPI N/A
- HRTX N/A
- EPS
- JPI N/A
- HRTX N/A
- Revenue
- JPI N/A
- HRTX $148,518,000.00
- Revenue This Year
- JPI N/A
- HRTX $12.08
- Revenue Next Year
- JPI N/A
- HRTX $12.57
- P/E Ratio
- JPI N/A
- HRTX N/A
- Revenue Growth
- JPI N/A
- HRTX 12.43
- 52 Week Low
- JPI $16.02
- HRTX $1.04
- 52 Week High
- JPI $19.12
- HRTX $2.88
- Technical
- Relative Strength Index (RSI)
- JPI 48.00
- HRTX 33.84
- Support Level
- JPI $20.32
- HRTX $1.66
- Resistance Level
- JPI $20.70
- HRTX $1.90
- Average True Range (ATR)
- JPI 0.18
- HRTX 0.08
- MACD
- JPI -0.01
- HRTX -0.03
- Stochastic Oscillator
- JPI 31.39
- HRTX 20.93
About JPI Nuveen Preferred and Income Term Fund of Beneficial Interest
Nuveen Preferred and Income Term Fund is a closed-end management investment company. Its investment objective is to provide a high level of current income and total return. The company's products include mutual funds, closed-end funds, Exchange-traded funds, Multi-asset model portfolios, and others.
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.